Sofracort · DIN 02224623 · 5 mg & 50 mcg & 0.5 mg/mL · Oph/Ot Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Sofracort · DIN 02224623
Manufacturer: Sanofi Aventis Pharma; listing date 2001-10-11
Health Canada: Marketed since 2024-07-30 · brand SOFRACORT · ATC S03CA01 DEXAMETHASONE AND ANTIINFECTIVES, S03CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Drops · route Ophthalmic, Otic · ingredients FRAMYCETIN SULFATE 5 MG/ML, DEXAMETHASONE (DEXAMETHASONE SODIUM METASULPHOBENZOATE) 0.5 MG/ML, GRAMICIDIN 0.05 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
Sofracort: Formulary list price $2.22 per unit (the source does not state the unit; exact figure $2.2212). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02224623)
Source record
DIN 02224623: Sofracort
Raw flags: sec3=Y
Item: 520404012; group id 577; item number 1532; lccId None; manufacturer id SAV
Source form: Oph/Ot Sol; strength: 5mg & 50mcg & 0.5mg/mL
Recorded listing: General benefit
Source prices (unrounded): $2.2212; ministry $2.2212
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02224623
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363
Therapeutic Notes (formulary)
The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
Shortage status: resolved shortage (ended October 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02224623
Shortage record checked October 6, 2026